|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
106,883,000 |
Market
Cap: |
1.04(M) |
Last
Volume: |
9,926 |
Avg
Vol: |
73,812 |
52
Week Range: |
$0.009725 - $0.02 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile RegeneRX Biopharmaceuticals is a biopharmaceutical company focused on the development of a therapeutic peptide, Thymosin beta 4 (Tss4), for tissue and organ protection, repair, and regeneration. Co. has formulated Tss4 into three product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sinaf S.a. |
10% Owner |
|
2017-10-13 |
4 |
A |
$0.00 |
$0 |
D/D |
266,667 |
11,649,370 |
|
- |
|
Sinaf S.a. |
10% Owner |
|
2017-10-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,671,296 |
11,382,703 |
|
- |
|
Goldstein Allan L |
Director |
|
2017-01-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
125,000 |
681,743 |
|
- |
|
Finkelstein J J |
President and CEO |
|
2016-12-30 |
5 |
GD |
$0.00 |
$0 |
D/D |
100,000 |
1,388,188 |
|
- |
|
Finkelstein J J |
President and CEO |
|
2016-12-01 |
5 |
|
$0.00 |
$0 |
D/D |
210,550 |
1,488,188 |
|
- |
|
Finkelstein J J |
President and CEO |
|
2016-12-01 |
5 |
A |
$0.00 |
$0 |
D/D |
210,550 |
1,488,188 |
|
- |
|
Goldstein Allan L |
Director |
|
2016-04-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
65,000 |
806,743 |
|
- |
|
Goldstein Allan L |
Director |
|
2016-04-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
60,000 |
871,743 |
|
- |
|
Finkelstein J J |
President and CEO |
|
2015-03-25 |
5 |
GD |
$0.00 |
$0 |
D/D |
100,000 |
1,277,638 |
|
- |
|
Goldstein Allan L |
Director |
|
2015-03-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
125,000 |
931,743 |
|
- |
|
Digital Aria |
10% Owner |
|
2014-08-29 |
4 |
OE |
$0.12 |
$1,000,000 |
D/D |
8,333,333 |
19,583,333 |
|
- |
|
Goldstein Allan L |
Director |
|
2014-06-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
250,103 |
1,056,743 |
|
- |
|
Digital Aria |
10% Owner |
|
2014-03-28 |
4 |
OE |
$0.12 |
$1,350,000 |
D/D |
11,250,000 |
11,250,000 |
|
- |
|
Sinaf S.a. |
10% Owner |
|
2014-02-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(64,575) |
11,584,795 |
|
- |
|
Defiante Farmaceutica Lda |
10% Owner |
|
2011-01-05 |
4 |
B |
$0.27 |
$250,000 |
I/I |
925,926 |
12,937,111 |
1.5 |
- |
|
Cavazza Claudio |
10% Owner |
|
2011-01-05 |
4 |
B |
$0.27 |
$600,000 |
I/I |
2,222,222 |
12,937,111 |
1.5 |
- |
|
Cavazza Paolo |
10% Owner |
|
2011-01-05 |
4 |
B |
$0.27 |
$600,000 |
I/I |
2,222,223 |
12,937,111 |
1.5 |
- |
|
Sinaf S.a. |
10% Owner |
|
2011-01-05 |
4 |
B |
$0.27 |
$350,000 |
D/D |
1,296,297 |
9,711,407 |
2.45 |
- |
|
Goldstein Allan L |
Director |
|
2010-12-07 |
5 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
1,536,846 |
|
- |
|
Goldstein Allan L |
Director |
|
2010-09-15 |
5 |
GD |
$0.00 |
$0 |
D/D |
30,000 |
1,556,846 |
|
- |
|
Sinaf S.a. |
10% Owner |
|
2010-06-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,415,110 |
|
- |
|
Lyons C Neil |
CFO & Treasurer |
|
2010-06-11 |
4 |
B |
$0.28 |
$4,266 |
D/D |
15,000 |
30,000 |
2.66 |
- |
|
Lyons C Neil |
CFO & Treasurer |
|
2010-06-10 |
4 |
B |
$0.28 |
$1,422 |
D/D |
5,000 |
15,000 |
2.66 |
- |
|
Cavazza Paolo |
10% Owner |
|
2010-05-21 |
4 |
B |
$0.00 |
$0 |
I/I |
240,000 |
240,000 |
1.42 |
- |
|
Finkelstein J J |
President and CEO |
|
2010-02-02 |
5 |
GD |
$0.00 |
$0 |
D/D |
500 |
1,377,638 |
|
- |
|
140 Records found
|
|
Page 2 of 6 |
|
|